Testing a new medication to prevent blood cancer relapse after initial treatment

Plain-English translation of NCT07509151 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new medication called to see if it can help people with certain types of blood cancer stay well after their initial treatment. The study compares two groups: one group will receive the medication for six months after completing standard cancer therapy, and the other group will simply be monitored without additional treatment. Researchers want to know if this extra step helps prevent the cancer from coming back.

Some people with this type of blood cancer have aggressive disease that tends to return even after successful initial treatment. This trial is testing whether giving the medication as a consolidation therapy—a follow-up step after standard treatment—can help keep the cancer from returning and improve long-term outcomes.

Do you qualify?

You likely qualify if…

you have been diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma with specific genetic features
you have received and responded well to standard first-line cancer treatment
you have adequate heart, kidney, and liver function as measured by blood tests
you are in good enough overall health to participate (ECOG performance status 0–2)
if female, you are not able to become pregnant or you are willing to use effective contraception during the trial

You likely don't qualify if…

you have evidence that your cancer has transformed into a more aggressive form
you have or have had cancer involvement in your central nervous system or brain
you have an active infection that requires treatment or are living with HIV, hepatitis B, or hepatitis C
you have a known severe heart condition or major cardiac abnormalities
you have had an allergic reaction to surovatamig or need ongoing immunosuppressive therapy for another condition

What participation looks like

If you join this trial, you will first be assigned to either receive the medication or to be monitored without additional treatment. If assigned to the medication group, you will receive injections under your skin once every 28 days for six cycles (about 6 months total). If assigned to the observation group, you will have check-up visits and monitoring for 24 weeks. Either way, you'll have regular blood tests and scans to track how you're doing, and the research team will carefully watch for any side effects or signs of cancer returning.

AI-generated summary from trial data · Aug 2, 2026 · Not medical advice

Trial locations(30 sites)

Australia

Research Site, Adelaide

Research Site, Fitzroy

Research Site, Heidelberg

Research Site, Nedlands

Research Site, Perth